Navigation Links
Children's Memorial Research Center, Chicago Becomes a Member of GeneGo's MetaMiner Stem Cell Partnership Program
Date:4/14/2009

ST. JOSEPH, Mich., April 14 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that Professor Marcelo Bento Soares of Children's Memorial Research Center has joined the MetaMiner Stem Cell Partnership Program. The goal of the program is to develop a series of blueprint pathway maps for adult, embryonic, fetal, fibroblasts, hematopoietic, mesenchymal, multipotent, neoplastic, pluripotent and totipotent stem cells.

"We feel that it is important to support such an initiative as there is a lot of stem cell information in the literature but no one has brought it all together in a set of comprehensive pathway maps," said Professor Marcelo Bento Soares, Director, Cancer Biology and Epigenomics Program. "This initiative will allow researchers to have more of a global perspective and allows newcomers to the field to get up to speed quickly."

"We had our kick off meeting last month and it went very well; we have a lot of other companies and academic groups that want to join this important project as this will be the first stem cell pathway platform for researchers to advance science. Stem cell research is attracting a lot of attention at the moment," said Julie Bryant, GeneGo's VP of Business Development. "We have a lot of experience in building pathway maps and we plan to have 10 types of stem cell drug centric pathway maps completed in 24 months."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.2(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.2(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

About Children's Memorial Research Center

The mission of Children's Memorial Research Center is to generate new knowledge leading to advancements in the prevention, diagnosis, and treatment of diseases that affect the development of children through adolescence as well as adult disorders that derive from them. Our multidisciplinary teams of physicians, scientists, technicians, nurses and trainees are committed to making discoveries that will improve the lives of children and their families.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
2. Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program
3. RF Technologies(R) Installs Safe Place(R) Solution for Pediatric and Infant Security at ProHealth Cares Waukesha Memorial Hospital
4. Rice Memorial Hospital Implements SinglePointe(TM) Automated Patient-Specific Management Solution From Omnicell
5. Pfizer Animal Health and NTRA Charities Team Up to Benefit the Barbaro Memorial Fund
6. Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
7. Memorial Medical First in Stanislaus County to Provide Convertible Ultrasound From ZONARE
8. New Weapon in BioDefense Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague
9. Latest BioTrends Research Reports to Assess the Impact of the Withdrawal of Raptiva (efalizumab) on the Psoriasis Market
10. ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program
11. Researchers develop new way to see single RNA molecules inside living cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 Roka Bioscience, Inc. ... testing solutions for the detection of foodborne pathogens,  today announced ... Sidoti & Company Spring 2017 Convention on March 29 at ... York Marriott Marquis. About Roka Bioscience ... Roka ...
(Date:3/27/2017)... 2017 Infectex Ltd., a Russian portfolio company of Maxwell Biotech ... SQ109 added to the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis ... ( USA ) and the US National Institutes of Health. ... ... Fund Logo ...
(Date:3/27/2017)... , ... March 27, 2017 , ... PMG Research ... Collaborations (CTC) conference presented by The Conference Forum in Boston on April 3-4, ... collaborate to drive improved clinical trial outcomes and bring them closer to the patient. ...
(Date:3/27/2017)... NEW YORK , March 27, 2017 /PRNewswire/ ... company developing novel therapies for neurodegenerative diseases, including ... confirmation that its application to list the Company,s ... been approved by The NASDAQ Stock Market, a ... of the listing, Neurotrope will ring the Opening Bell ...
Breaking Biology Technology:
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ... Iris-Scan, wird seine erstklassige biometrische Lösung zur ... 835 mit X16 LTE auf dem Mobile ... März) am Qualcomm-Stand in Halle 3, Stand ... beinhaltet die Sicherheitsplattform Qualcomm Haven™ – eine ...
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. 22, ... Avamere Family of Companies (Avamere Health Services, Infinity Rehab, ... six-month research study that will apply the power of ... senior living and health centers. By analyzing data streaming ... gain insights into physical and environmental conditions, and obtain ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special Counsel to ... of Identity Strategy Partners, LLP, today releases the following ... Protecting the Nation From Foreign Terrorist Entry Into the ... Trump,s ,Travel Ban, Executive Order gains more notoriety and ... ban, it is important that our national discourse regain ...
Breaking Biology News(10 mins):